



26 October 2020

Novartis Pharma AG
Basel, Switzerland
CH-4002

Reference: EudraCT 2018-004381-33 Novartis Protocol ID CQAW039A2127.

Randomized, subject and investigator blinded, placebo-controlled study to demonstrate the anti-inflammatory effect of fevipirant (QAW039) in moderate-severe asthma patients with high sputum and blood eosinophils.

Trial 2018-004381-33 was cancelled with no patient enrollment and as such, no results will be reported.